These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1355522)

  • 1. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.
    Leitzel K; Teramoto Y; Sampson E; Mauceri J; Langton BC; Demers L; Podczaski E; Harvey H; Shambaugh S; Volas G
    J Clin Oncol; 1992 Sep; 10(9):1436-43. PubMed ID: 1355522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
    Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
    J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
    Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
    J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy.
    Meden H; Marx D; Fattahi A; Rath W; Kron M; Wuttke W; Schauer A; Kuhn W
    J Cancer Res Clin Oncol; 1994; 120(6):378-81. PubMed ID: 7908021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients.
    Meenakshi A; Kumar RS; Kumar NS
    J Immunoassay Immunochem; 2002; 23(3):293-305. PubMed ID: 12227416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.
    Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT
    Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer.
    Isola JJ; Holli K; Oksa H; Teramoto Y; Kallioniemi OP
    Cancer; 1994 Feb; 73(3):652-8. PubMed ID: 7905363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells.
    Mori S; Mori Y; Mukaiyama T; Yamada Y; Sonobe Y; Matsushita H; Sakamoto G; Akiyama T; Ogawa M; Shiraishi M
    Jpn J Cancer Res; 1990 May; 81(5):489-94. PubMed ID: 1974247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
    Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
    Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients.
    Breuer B; De Vivo I; Luo JC; Smith S; Pincus MR; Tatum AH; Daucher J; Minick CR; Miller DG; Nowak EJ
    Cancer Epidemiol Biomarkers Prev; 1994; 3(1):63-6. PubMed ID: 7906981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
    Langton BC; Crenshaw MC; Chao LA; Stuart SG; Akita RW; Jackson JE
    Cancer Res; 1991 May; 51(10):2593-8. PubMed ID: 1673637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and utilization of two novel anti-erbB-2 monoclonal antibodies in detection of soluble ErbB-2 for breast cancer prognosis.
    Li P; Li Y; Li JY; Liu J
    Cancer Lett; 2003 Apr; 193(2):139-48. PubMed ID: 12706870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of sandwich radioimmunometric assay for serum c-erbB-2 oncogene product and its significance in diagnosing breast carcinoma].
    Yu FZ; Sugano K; Ohkura H; Mori S
    Rinsho Byori; 1991 Oct; 39(10):1087-92. PubMed ID: 1684826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of serum c-erbB-2 protein in breast cancer patients.
    Willsher PC; Beaver J; Pinder S; Bell JA; Ellis IO; Blamey RW; Robertson JF
    Breast Cancer Res Treat; 1996; 40(3):251-5. PubMed ID: 8883967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
    McKenzie SJ; DeSombre KA; Bast BS; Hollis DR; Whitaker RS; Berchuck A; Boyer CM; Bast RC
    Cancer; 1993 Jun; 71(12):3942-6. PubMed ID: 8099528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
    Wu JT; Astill ME; Gagon SD; Bryson L
    J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial serum c-erbB-2 levels in patients with breast carcinoma.
    Volas GH; Leitzel K; Teramoto Y; Grossberg H; Demers L; Lipton A
    Cancer; 1996 Jul; 78(2):267-72. PubMed ID: 8674002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonspecific cross-reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer.
    Allard WJ; Neaman IE; Elting JJ; Barnett TR; Yoshimura H; Fritsche HA; Yeung KK
    Cancer Res; 1994 Mar; 54(5):1227-34. PubMed ID: 8118811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.
    Mabrouk RA; Ali-Labib R
    Clin Biochem; 2003 Oct; 36(7):537-43. PubMed ID: 14563447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.
    Thor AD; Schwartz LH; Koerner FC; Edgerton SM; Skates SJ; Yin S; McKenzie SJ; Panicali DL; Marks PJ; Fingert HJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7147-52. PubMed ID: 2573426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.